Samsung's Lee fined over illegally using propofol

Samsungs de facto chief Lee Jae-yong was fined 70 million won about 60,000 on Tuesday for illegally using the anesthetic drug propofol, about two months after he was released on parole over a separate corruption case.The Seoul Central District Court said it convicted Lee, vice-chairman of Samsung Electronics, of violating a law on drug controls.


PTI | Seoul | Updated: 26-10-2021 17:38 IST | Created: 26-10-2021 17:20 IST
Samsung's Lee fined over illegally using propofol
Representative Image Image Credit: Flickr
  • Country:
  • South Korea

Samsung's de facto chief Lee Jae-yong was fined 70 million won (about $60,000) on Tuesday for illegally using the anesthetic drug propofol, about two months after he was released on parole over a separate corruption case.

The Seoul Central District Court said it convicted Lee, vice-chairman of Samsung Electronics, of violating a law on drug controls. It said Lee was also ordered to forfeit about 10 million won ($8,570).

Lee, who is the third-generation heir of South Korea's biggest company, Samsung, has been involved in a series of corruption cases lately. The company's crown jewel, Samsung Electronics, singlehandedly represents about 20 percent of South Korea's entire stock market value and one-fourth of its total exports.

Prosecutors earlier accused Lee of taking propofol at a hospital in Seoul about 40 times for non-medical purposes. Lee's lawyers said he took propofol in line with a doctor's prescription, according to the court.

Propofol is used for anesthesia and sedation. Its use gained notoriety in 2009 when pop star Michael Jackson died of a propofol overdose.

In August, Lee was released from prison after serving 18 months of a 30-month sentence for embezzling millions of dollars from corporate funds to bribe then-President Park Geun-hye. The bribery scheme was to ensure Geun-Hye's support for a 2015 merger between two Samsung affiliates that tightened Lee's control over the corporate empire.

Lee is also facing a separate court trial over alleged stock price manipulation, auditing violations, and other financial crimes related to the 2015 merger.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback